Estimating the economic benefits of positive shifts in fibromyalgia severity: An exploratory analysis based on modeling of clinical trial data of pregabalin

Journal of Medical Economics

Volumn 16, Issue 1, 2013, Pages 55-61

  Cappelleri, Joseph C ^a   Bushmakin, Andrew G ^a   Zlateva, Gergana ^a   Chandran, Arthi ^a  

^a PFIZER INC   (United States)

Author keywords

Costs; Fibromyalgia; Pregabalin; Severity

Indexed keywords

PLACEBO; PREGABALIN;

ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; EXPLORATORY RESEARCH; FEMALE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; STATISTICAL MODEL;

ADULT; ANALGESICS; COSTS AND COST ANALYSIS; FEMALE; FIBROMYALGIA; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 84870873613     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.727930     Document Type: Article

References (36)

1. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72
2. Bennett RM, Jones J, Turk DC, et al. An internet survey of 2596 people with fibromyalgia. BMC Musculoskelet Disord 2007;8:27
3. Arnold LM, Crofford LJ, Mease PJ, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns 2008;73:114-20
4. Silverman S, Sadosky A, Evans C, et al. Toward characterization and definition of fibromyalgia severity. BMC Musculoskelet Disord 2010;11:66
5. Wolfe F, Clauw DJ, Fitzcharles M-A, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010;62:600-10
6. Mease P, Arnold LM, Choy EH, et al. Fibromyalgia Syndrome Module at OMERACT 9: Domain Construct. J Rheumatol 2009;36:2318-29
7. Hughes G, Martinez C, Myon E, et al. The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK. An observational study based on clinical practice. Arthritis Rheum 2006;54:177-83 (Pubitemid 43122200)
8. Berger A, Dukes E, Martin S, et al. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract 2007;61:1498-508 (Pubitemid 47228612)
9. White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: Medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008;50:13-24
10. Berger A, Sadosky A, Dukes E, et al. Characteristics and patterns of healthcare utilization of patients with fibromyalgia in general practitioner settings in Germany. Curr Med Res Opin 2008;24:2489-99
11. Sicras-Mainar A, Rejas J, Navarro R, et al. Treating patients with fibromyalgia in primary care settings under routine medical practice: A claim database cost and burden of illness study. Arthritis Res Ther 2009;11:R54
12. Robinson RL, Birnbaum HG, Morley MA, et al. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 2003;30:1318-25 (Pubitemid 36666360)
13. Kleinman N, Harnett J, Melkonian A, et al. Burden of fibromyalgia and comparisons with osteoarthritis in the workforce. J Occup Environ Med 2009; 51:1384-93
14. Chandran A, Schaefer C, Ryan K, et al. The comparative economic burden of mild, moderate, and severe fibromyalgia: Results from a retrospective chart review and a cross-sectional survey of working-age U.S. adults. J Manag Care Pharm 2012;18:415-26
15. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: Development and validation. J Rheumatol 1991;18:728-33
16. Field MJ, Cox PJ, Stott E, et al. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci USA 2006;103: 17537-42 (Pubitemid 44789004)
17. Errante LD, Petroff OA. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure 2003;12:300-6 (Pubitemid 36806076)
18. Cunningham MO, Woodhall GL, Thompson SE, et al. Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci 2004;20:1566-76 (Pubitemid 39294695)
19. Maneuf YP, Hughes J, McKnight AT. Gabapentin inhibits the substance P-facilitated K()-evoked release of [(3)H]glutamate from rat caudial trigeminal nucleus slices. Pain 2001;93:191-6 (Pubitemid 32568405)
20. Pfizer Inc. Lyrica- [pregabalin] capsules prescribing information. New York, NY: Pfizer Inc, 2012
21. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebocontrolled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35:502-14 (Pubitemid 351374429)
22. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blind, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008;9:792-805
23. Pauer L, Winkelmann A, Arsenault P, et al. An international, randomized, double-blind, placebo-controlled, phase III Trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol 2011; 38:2643-52
24. Bennett RM, Bushmakin AG, Cappelleri JC, et al. Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol 2009; 36:1304-11
25. Arnold LM, Emir B, Murphy TK, et al. Safety profile and tolerability of up to 1 year of pregabalin treatment in 3 open-label extension studies in patients with fibromyalgia. Clin Ther 2012;34:1092-102
26. Centers for Medicare & Medicaid. www.cms.gov. A federal government website managed by the Centers for Medicare & Medicaid Services, 7500 Security Boulevard, Baltimore, MD, 21244. Accessed November 18, 2011
27. Tzellos TG, Toulis KA, Goulis DG, et al. Gabapentin and pregabalin in the treatment of fibromyalgia: A systematic review and a meta-analysis. J Clin Pharm Ther 2010;35:639-56
28. Straube S, Derry S, Moore RA, et al. Pregabalin in fibromyalgia: Meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford) 2010;49:706-15
29. Lachaine J, Beauchemin C, Landry PA. Clinical and economic characteristics of patients with fibromyalgia syndrome. Clin J Pain 2010;26:284-90
30. Palacio A, Uribe CL, Li H, et al. Financial and clinical characteristics of fibromyalgia: A case-control comparison. Am J Manag Care 2010; 16(Suppl):S118-S25
31. Schaefer C, Chandran A, Hufstader M, et al. The comparative burden of mild, moderate and severe fibromyalgia: Results from a cross-sectional survey in the United States. Health Qual Life Outcomes 2011;9:71
32. Kleinman NL, Sanchez RJ, Lynch WD, et al. Health outcomes and costs among employees with fibromyalgia treated with pregabalin vs. standard of care. Pain Pract 2011;11:540-51
33. Burke JP, Sanchez R, Joshi AV, et al. Health care costs in patients with fibromyalgia on pregabalin vs. duloxetine. Pain Pract 2011;12:14-22
34. Harnett J, Margolis J, Cao Z, et al. Real-world evaluation of health-care resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine. Pain Pract 2011;11:217-29
35. Gore M, Tai K-S, Chandran A, et al. Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care. J Med Econ 2012; 15:19-31
36. Zhao Y, Sun P, Watson P, et al. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia. Pain Pract 2011;11:204-16